The collaboration, across multiple therapeutic
areas, will evaluate how polygenic risk scores could be used to
improve clinical trial design and efficiency
OXFORD,
England, April 30, 2024 /PRNewswire/ -- Genomics
plc and GSK announced a new collaboration to explore the potential
for using polygenic risk scores (PRS) in clinical trials, to
improve understanding of disease risk and patient selection, which
could support optimisation of trial design. Genomics plc is a
global leader in PRS-powered technologies and approaches and has
developed extensive genetic databases and algorithms to understand
the genetic component of diseases.
Genomics plc and GSK will investigate several applications for
Genomics' suite of PRS-powered tools, including the potential for
PRS tools to reduce the number of trial participants and shortening
study timescales and improving outcomes of both proof-of-concept
and pivotal trials.
Professor Sir Peter Donnelly
FRS, FMedSci, Founder and Chief Executive Officer, Genomics
plc:
"We could not be more excited to be collaborating with
GSK on this programme. PRS-based approaches have the potential to
support clinical trial design. Using PRS to get the right people
into studies could have a potential positive impact, including in
the reduction of trial size and timescale, leading to efficiencies
in drug development."
Genetic factors play a key role in disease susceptibility,
progression, and response to drugs. These effects are often a
result of many thousands of genetic changes that can be captured as
a single number or PRS. This work will explore the opportunity for
PRS-based approaches to support patient selection, and understand
how that may impact clinical trials through reducing the number of
patients recruited or shortening the duration of trials.
Robert Scott, Vice President
of Human Genetics and Genomics at GSK: "Genomics plc is leading
in both the development and real-world application of PRS-based
approaches, opening up new frontiers in genomic medicine. At GSK,
we have demonstrated the opportunity for genetics to guide drug
discovery and development; I look forward to working with Genomics
plc to further explore the potential for PRS to support clinical
trial design."
About Genomics plc
Genomics plc is a pioneering healthcare company that aims to
transform health through the power of genomics. In 2014, Professor
Sir Peter Donnelly and three
colleagues founded Genomics plc, spinning it out of the
University of Oxford. The company,
which now employs more than one hundred people in the UK and the
US, has an extensive data platform and cutting-edge analytical
technology to enable prevention-first approaches to individual
and population health. Genomics plc is the global leader in
PRS-powered technology. Its powerful risk prediction tools can get
more of the right people into the appropriate screening, diagnosis,
and treatment pathways they need. Genomics' core technology
also supports a suite of products for the life sciences sector,
enabling the successful discovery and validation of new
drug targets, optimized clinical trial design and efficiency, and
the development of novel companion diagnostics. For additional
information about Genomics plc, please
visit www.genomicsplc.com
Contact
BAM for Genomics plc: genomicsplc@bamtheagency.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genomics-plc-and-gsk-establish-precision-medicine-collaboration-to-assess-polygenic-risk-scores-in-clinical-trial-design-302131676.html
SOURCE Genomics plc